About NVIGEN
NVIGEN is a company based in Sunnyvale (United States) founded in 2011. NVIGEN has raised $2.23 million across 4 funding rounds from investors including NIH, HHS and Danen Ventures. The company has 8 employees as of December 31, 2022. NVIGEN offers products and services including NVIGEN X™, MagVigen™, NERNST-Seq™, and On-Bead ELISA Kit. NVIGEN operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Sunnyvale, United States
- Employees 8 as on 31 Dec, 2022
-
Sectors
HealthcareTechnology Chemicals & Materials
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nvigen
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.23 M (USD)
in 4 rounds
-
Latest Funding Round
$1.12 M (USD), Seed
Mar 18, 2014
-
Investors
NIH
& 4 more
-
Employee Count
8
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NVIGEN
NVIGEN offers a comprehensive portfolio of products and services, including NVIGEN X™, MagVigen™, NERNST-Seq™, and On-Bead ELISA Kit.
NGS and multiomics test for early cancer recurrence prediction.
Tools for DNA extraction and purification in diagnostics.
Enhanced single cell RNA sequencing with spatial resolution.
Nanoparticle-based ELISA for sensitive protein biomarker detection.
People of NVIGEN
Unlock access to complete
Unlock access to complete
Funding Insights of NVIGEN
NVIGEN has successfully raised a total of $2.23M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $1.12 million completed in March 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NVIGEN
NVIGEN has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Danen Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Chinese venture fund in Silicon Valley
|
Locked | Locked | Locked | |
|
Investments are directed toward seed-stage startups by CRCM Ventures.
|
Locked | Locked | Locked |
Investor details for NVIGEN
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NVIGEN
Investment portfolio details for NVIGEN
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NVIGEN
Detailed financials for NVIGEN
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nvigen Comparisons
Peer comparison for NVIGEN
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NVIGEN
NVIGEN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of NVIGEN
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nvigen
Complete news archive for NVIGEN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NVIGEN
NVIGEN was founded in 2011 and raised its 1st funding round 1 year after it was founded.
NVIGEN is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Aihua Fu is the current CEO of NVIGEN.
NVIGEN is a funded company, having raised a total of $2.23M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at NVIGEN is 8.
NVIGEN was established in 2011 in Sunnyvale, United States, within the biotechnology sector focused on nanomaterials. Operations center on the development and provision of nanoparticle reagents, such as magnetic and fluorescent magnetic beads, alongside services like antibody purification and immunoprecipitation assays. These offerings support research into disease understanding, diagnosis, and treatment, with activities conducted primarily in the U.S.
NVIGEN's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
NVIGEN offers NVIGEN X™, MagVigen™, NERNST-Seq™, and On-Bead ELISA Kit.
NVIGEN has 5 investors. Key investors include NIH, HHS, Danen Ventures, TSVC, and CRCM Ventures.